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Abstract Intravenous loop diuretics are still the corner-
stone of therapy in acute decompensated heart failure,
however, the optimal dosage and administration strategies
remain poorly defined particularly in patients with an
associated renal dysfunction. This is a single-center, pilot,
randomized trial involving patients with acute HF and renal
dysfunction. Patients were assigned to receive continuous
furosemide infusion (cIV) or bolus injections of furosemide
(iIV). Primary end points were the evaluation of urine
output volumes, renal function, and b-type natriuretic
peptide (BNP) levels during treatment time. Secondary
end point included: weight loss, length of hospitalization,
differences in plasma electrolytes, need for additional
treatment, and evaluation of cardiac events during
follow-up period. 57 patients were included in the study.
The cIV group showed an increase in urine output
(2,505 ± 796 vs 2140 ± 468 ml/day, p \ 0.04) and a
more significant decrease of BNP levels in respect to the
iIV group (679.6 ± 397 vs 949 ± 548 pg/ml, p \ 0.04).
We observed a significant increase in creatinine levels
(1.78 ± 0.5 vs 1.41 ± 0.3 mg/dl, p \ 0.01), and a reduc-
tion of the estimated glomerular filtration rate in cIV
(44.8 ± 6.1 vs 46.7 ± 6.1 ml/min, p \ 0.05). We observed
a significant difference in eGFR (p = 0.01), creatinine
(p = 0.02) and BNP levels (p = 0.03) from baseline to the
end of treatment in both groups. A significant increase of in-
hospital additional treatment as well as length of hospital-
ization was observed in cIV. Finally, cIV revealed a higher
rate of adverse events during the follow-up period
(p \ 0.03). cIV appears to provide a more efficient diuresis
and BNP level reduction during hospitalization, however, it
was associated with increased rate of worsening renal
function during hospitalization. cIV also appears related to
a longer hospitalization and an increased number of adverse
events during follow-up. For all of these reasons, a larger
multi-center study is required to determine whether high-
dose diuretics are responsible for worsening renal function
and to define the best modality of administration.
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Introduction
The use of intravenous loop diuretics is still the cor-
nerstone of acute decompensated heart failure (ADHF)
treatment, especially in patients admitted with pulmonary
congestion and volume overload. Significant concerns
have been raised regarding the risks and the benefits of
loop diuretics, especially involving the modality of
administration and mean dosage and administration reg-
imens [1, 2]. Current Guidelines recommend the use of
loop diuretics to reduce left ventricular filling pressure
and peripheral fluid retention, and to avoid pulmonary
edema. Despite the high prevalence of their use, high
quality data supporting diuretic safety and efficacy in
this setting are lacking. In particular, specific reports
comparing intermittent versus continuous administration
in a step by step modality infusion have not yet been
reported. Renal dysfunction is a clinical condition often
associated with high doses of loop diuretics and poor
outcome; however, patients with severe Renal Insuffi-
ciency have often been excluded from clinical trials [4,
5]. Although loop diuretics are the most commonly used
drugs in HF treatment, their short- and long-term effects
are relatively unknown. Therefore, it remains unclear if
continuous infusion of loop diuretics is better than
intermittent infusion in terms of diuresis efficacy, wors-
ening of renal dysfunction and long-term prognosis. Most
of the reported studies do not provide a dose escalation
algorithm with a fixed dosage administration and the best
diuretic dosage amount [6, 7]. For all these reasons, we
thought that a dose layout is currently lacking, and it
appears mandatory to achieve a scheme for modality
administration and step by step increasing dosing.
Recently, a multi-center trial on this topic (DOSE HF)
evaluated how various doses and regimes of loop
diuretics affect renal function, clinical status and early
mortality. This study did not reveal a better outcome in
either primary or secondary end points when comparing
continuous infusion to a bolus regimen [8]. Given the
conflicting data from literature, we aimed to evaluate the
effects of a continuous infusion of furosemide compared
to a bolus daily regimen at similar doses by assessing
changes in urine output volumes, renal function and
b-type natriuretic peptide (BNP) levels in patients with
ADHF and mild renal dysfunction in a fixed dose pro-
tocol study based on diuresis response. Secondary end
points were weight loss, length of hospitalization, need
for additional therapy during infusion period, electrolyte
imbalance and follow-up evaluation during a 6 months
post discharge observational period.
Methods
Study protocol
This was a prospective, randomized, open label, single
center pilot study, comparing continuous with intermittent
infusion of furosemide in patients admitted with a diagnosis
of ADHF into our tertiary-care medical center. Patients were
enrolled consecutively from the Department of Internal
Medicine, Cardiology Section Centre into a Para-Intensive
Unit (Siena, Italy) from April 2011 to December 2012. We
initially evaluated 94 patients; 22 were excluded because of
normal renal function at baseline, 11 for receiving different
dosages of intravenous furosemide, 4 for isolated diastolic
HF (following the Consort diagram). The remaining 58
patients were randomized to receive continuous or inter-
mittent intravenous furosemide administration. All the
enrolled patients had continuous ECG and blood pressure
monitoring combined with urine output measurement.
Patients were eligible if they were admitted with a pri-
mary diagnosis of ADHF, randomized within 12 h after
hospital presentation, and with evidence of volume over-
load (pulmonary congestion) on a chest X-ray study and
had BNP levels [100 pg/ml. Patients also displayed mild
to moderate renal dysfunction with creatinine values up to
1.4 mg/dl. Some patients were supported with non invasive
ventilation before randomization. Once the initial 12 h
dose was determined, patients were randomized using a 1:1
ratio using a computer-generated scheme to receive the
furosemide dose either divided into a twice-daily bolus
injection or in a continuous infusion (mixed as a 1:1 ratio in
5 % dextrose in water) for a time period ranging from 72 to
120 h. The randomization was casual, and the physicians
did not previously know the assigned arm. The dose
escalation and subsequent titration of furosemide was
guided by clinical response in terms of urine output volume
and body weight reduction (Fig. 1). Before randomization,
renal function parameters and BNP levels were measured
in all patients. Subsequent titration of the furosemide
dosage was at the discretion of the attending physician, but
was guided by a dose-escalation algorithm based on the
treatment response (weight loss and urine output volume),
symptom improvement, changes in renal function, elec-
trolyte balance, and chest radiography. The specific doses
of furosemide and the use of additional agents to manage
ADHF (dopamine, IV vasodilators, hypertonic saline
infusion) were decided based upon blood pressure mea-
surements, renal function evaluation and diuresis response.
Supplementary treatment was left to the discretion of the
treating physician. The duration of infusion was continued
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for up to 72 h, at 48 h the physicians had the possibility to
adjust diuretic dose administration on the basis of the
clinical response. After 72 h the treatment could be stopped
or continued for an additional 36–48 h depending on the
patient’s condition and diuresis response. Acute kidney
injury (AKI) was defined following the RIFLE criteria [9].
The frequency of laboratory determination of electro-
lytes, renal function and BNP after the infusion period until
discharge was decided by the attending physician but was
guided by a dose-escalation algorithm.
This trial was approved by the Local Investigational
Human Review Board, and all patients gave their signed
informed consent.
Inclusion criteria
Patients were included if they met the diagnostic criteria of
acute HF associated with renal dysfunction. Patients
enrolled had ADHF showing at least one of the following
symptoms: dyspnoea, orthopnoea, peripheral oedema or
major fatigue, In addition, patients had to exhibit at least
two clinical signs such as rales, pulmonary congestion on
chest radiography, jugular vein dilatation or a third cardiac
heart sound. They also showed an impaired Left Ventric-
ular Ejection Fraction (LVEF \45 %) with cardiac dilata-
tion or pulmonary hypertension. Coronary heart disease
information was gathered based on clinical history, evi-
dence of Q waves on the electrocardiograms, and regional
kinetic alterations on echocardiographic examination. In
our study, renal dysfunction was defined as creatinine value
[1.4 mg/dl and estimated glomerular filtration rate
(eGFR) less than 50 ml/min1.73 m2.
Exclusion criteria
Patients were excluded if they had received more than two
IV doses of furosemide or any continuous infusion of
furosemide 1 month before the randomization, if they had
end-stage renal disease or the need for renal replacement
therapy (dialysis or ultrafiltration), isolated diastolic dys-
function or recent myocardial infarction. Patients with a
systolic blood pressure lower than 80 mm Hg or with a
serum creatinine level greater than 6.0 mg/dl were also
excluded. Patients with recent contrast studies (cardiac
catheterization, iodate liquid administration) were also
excluded. Finally, patients taking neseritide thiazides or
tolvaptan during the in-hospital period were excluded.
Outcome measurement
The 3 primary objectives were: (1) evaluation of renal
function in terms of changes in creatinine levels and eGFR,
(2) evaluation of mean urine output volume during the
infusion period and (3) evaluation of BNP levels from
admission to the end of treatment in the two groups. Sec-
ondary endpoints included: weight loss, electrolyte balance
measurement, length of hospitalization, and need for
additional treatment; follow-up evaluation of composite
cardiac events in terms of death and re-hospitalization for
cardiovascular causes.
Adverse events definition
We evaluated two different timing points of adverse
events: in hospital and follow-up events. The in-hospital
Fig. 1 Algorithm of diuretic
treatment during randomization
and study period
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events encompassed the need for: saline solutions treat-
ment (for patients displaying Na? values\130 mEq during
furosemide infusion) and dobutamine infusion (for patients
with systolic blood pressure \90 mmHg), and major clin-
ical adverse events in terms of sudden death, acute coro-
nary syndrome, or acute renal insufficiency needing
haemodialysis. The 6-months follow-up events encom-
passed: cardiac death, rehospitalization for all cardiovas-
cular causes, and severe renal insufficiency needing
hemodialysis.
Laboratory analysis
Complete blood counts with Hb, Hct, red blood cell count,
serum creatinine, sodium, and potassium were performed
at the time of admission to determine the baseline criteria,
with subsequent testing performed each day during daily
infusions, and again at the time of discharge. The eGFR
was calculated using the modification of diet in renal dis-
ease [10].
Plasma BNP level was measured at the beginning and at
discharge, using the quantitative immunofluorescence
assay manufactured by Inverness (San Diego, CA,
USA).The analytic sensitivity of the assay is\5 pg/ml, and
the upper limit of normal is considered to be 400 pg/ml.
Statistical analysis
All data were analyzed with intention-to-treat. Continuous
variables are expressed as mean ± standard deviation (SD)
and compared with t test for independent groups. p values
\0.05 were considered significant. The treatment groups
defined by each treatment mode were compared with the
use of univariate analyses to assess the independent rela-
tionship between the two methods of furosemide infusion
and the respective outcomes. Kaplan–Meier methods were
employed to generate survival plots that were compared
using a log-rank test. Composite outcome were considered
the sum of total adverse events in terms of mortality and
rehospitalization for cardiac causes or acute renal insuffi-
ciency. All the analysis was performed by using the SPSS
13.0 for Windows (SPSS Inc, Chicago IL).
Sample size calculation
The sample size used was preliminarily calculated from
each co-primary endpoint. We included the following
assumptions: (1) a 30 % or more effect size in the differ-
ence between mean paired changes in continuous co-pri-
mary endpoints (eGFR, creatinine, BNP and diuresis);
standard variation of each group data not exceeding 20 %;
(2) alpha = 0.05 two-tailed and (3) power (1-beta) =
80 %. Thus, the considered sample size was 54 subjects
(27 in each group), which was the larger among each
endpoint; we assumed no patients would have withdrawn
or been lost during follow-up.
Results
A total of 58 consecutive patients with acute HF and renal
dysfunction were randomly assigned to one of the two
groups. One patient was excluded from the analysis
because of missing data regarding various laboratory
measurements. No patients died during hospital stay, and
all patients who needed dopamine infusion (n. 23) were
able to be discharged routinely. The group that received the
continuous infusion of furosemide (cIV), consisted of 30
patients. The second group that received the same drug in
Table 1 Clinical characteristics, risk factors and medication at
admission of the enrolled sample
cIV iIV
Age 71 ± 7 73 ± 8
Gender
Female 14 13
Male 16 15
Baseline weight 72 69.7
Blood pressure 120/75 125/80
Baseline creatinine (mg/dl) 1.63 ± 0.32 1.58 ± 0.24
eGFR (mg/ml) 45.2 ± 7.6 44.7 ± 7.7
Sodium baseline levels 137.2 ± 5 137.7 ± 5
Potassium baseline levels 4.19 ± 0.4 4.26 ± 0.5
Ejection fraction 34.3 ± 10 35.8 ± 8
NYHA class III 4 5
NYHA class IV 27 22
Risk factors (%)
Diabetes mellitus 55.2 61.1
Hypertension 89.4 87.9
Dyslipidemia 72.4 75
Previous CAD 46.2 49.4
Atrial fibrillation (%) 36.6 41.3
Baseline BNP (pg/ml) 1,204 ± 693 1,099 ± 571
Medication at admission (%)
Beta-blockers (%) 42 38
Aldosterone antagonists (%) 22 26
Ace inhibitors/angiotensin and or
ARBs (%)
63 65
Nitrates (%) 55 58
Aspirin (%) 65 62
Anticoagulants (%) 22 25
eGFR estimated glomerular filtration rate, BNP B-type natriuretic
peptide, CAD coronary artery disease, cIV continuous infusion, iIV
intermittent infusion, ARBs angiotensin receptor blockers
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bolus injections twice a day (iIV), consisted of 27 patients.
The mean doses of furosemide were similar in both groups
during the infusion period, and the median time from
presentation to randomization was 16 h. Table 1 shows the
patients’ characteristics of each group at admission. The
mean age was 72 ± 8 years, the mean ejection fraction
was 35 ± 10 %, the mean creatinine level was 1.7 ±
0.4 mg/dl, and the mean BNP level was 1,156 ± 640 pg/
ml. NIV therapy was performed in eight patients at hospital
admission during the first 12 h, before enrollment. Among
our patients, 64 % had ACE-inhibitors (enalapril or ram-
ipril) or angiotensin-receptor blockers, 40 % had beta-
blockers, 24 % aldosterone antagonist and the 56 % were
treated with nitrates. The median duration of study-drug
administration was 112 ± 24 h (110 ± 24 in cIV vs
120 ± 36 h in iIV). The mean dosage of furosemide was
188 ± 70 in cIV vs 170 ± 80 mg/day in iIV (NS). The
total amount of furosemide infusion was 1,030 ± 340 mg
in cIV and 980 ± 380 mg in iIV (NS).Other clinical
characteristics and risk factors were similar in both groups.
Primary end points
The mean urine output volume/24 h was greater in cIV
compared to the iIV arm (2,505 ± 796 vs 2,140 ± 468 ml,
p \ 0.04); analysis day by day during the infusion period
revealed that most of the diuresis occurred during the
second day after randomization (2,850 ± 720 cIV vs
2,560 ± 540 ml iIV, p \ 0.05). Renal function analysis
demonstrated a significant impairment in cIV in compari-
son with iIV after treatment: this was expressed by creat-
inine changes (1.78 ± 0.5 vs 1.41 ± 0.3 mg/dl, p \ 0.01)
as well as eGFR reduction (44.8 ± 6.1 vs 46.7 ± 6.1 ml/
min/1.73 m2, p \ 0.05). Daily analysis of renal function
demonstrated that AKI defined as creatinine [0.3 mg/dl,
happened during the late infusion period (fifth day): per-
centage of AKI in cIV was 33 % vs 17 % in iIV group
(p \ 0.01). On the other hand, BNP levels were signifi-
cantly reduced in the cIV group in comparison with the
iIV group(679.6 ± 397 vs 949 ± 548 pg/ml, p \ 0.01)
(Table 2). Difference in eGFR (p = 0.01), creatinine
(p = 0.02) and BNP levels (p = 0.03) from baseline to the
end of treatment in each group were significant (Table 3).
Outcome analysis and secondary endpoints
In the CiV group there were eight patients rehospitalized,
and six patients died during follow-up period. In the IiV
group there were six patients rehospitalized, and three died.
An increase in the number of adverse events was observed
in the CiV group respect to iIV group in regards to re-
hospitalization and for mortality (43 vs 34 %, p \ 0.03).
The Kaplan–Meier curve was significant for composite end
points during the 180 days follow-up period (Fig. 2).
Weight loss was measured after infusion period, and it was
similar in both arms (-4.4 ± 2.1 in cIV vs -3.8 ± 3.1 kg
in iIV; NS) (Table 3).
There were no significant differences in plasma
electrolytes between both groups, although patients with
cIV needed hypertonic saline solutions at a higher fre-
quency (40 vs 19 %, p \ 0.01). Dobutamine infusions
Table 2 Differences in urine output volumes, renal function and
BNP levels in both groups
cIV iIV p value
Urine output/24 h (ml) 2,505 ± 796 2,140 ± 468 0.04
Creatinine AT (mg/dl) 1.78 ± 0.5 1.51 ± 0.3 0.01
eGFR AT (ml/min1.73 m2) 44.8 ± 6.1 46.7 ± 6.1 0.05
BNP AT (pg/ml) 679.6 ± 397 949 ± 548 0.04
eGFR estimated glomerular filtration rate, BNP B-type natriuretic
peptide, AT after treatment, cIV continuous infusion, iIV intermittent
infusion
Table 3 Difference in D laboratory parameters and clinical factors
between each group from the admission to the discharge
cIV iIV p value
D Creatinine AT (mg/dl) -0.10 ± 0.30 -0.50 ± 0.34 0.02
Weight loss (kg) -4.4 ± 2.1 -3.8 ± 3.1 0.39
D eGFR AT (ml/
min1.73 m2)
-3.18 ± 2.45 -1.93 ± 2.90 0.01
D Sodium (mEq) -2.3 ± 5.2 -3.5 ± 6.5 0.28
D Potassium (mEq) -0.5 ± 1.1 -0.4 ± 0.7 0.83
D BNP AT (pg/ml) -525 ± 615 -148 ± 463 0.03
eGFR estimated glomerular filtration rate, BNP B-type natriuretic
peptide, AT after treatment, cIV continuous infusion, iIV intermittent
infusion
Fig. 2 Kaplan Meier curve for the combined risk of re-hospitaliza-
tion and mortality at 180 days in two groups
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were administered more frequently in cIV in comparison
with the iIV arm (50 vs 26 %, p \ 0.01). The length of
hospitalization was increased in cIV compared to iIV
(14.3 ± 5 vs 11.5 ± 4.3, p \ 0.03) (Fig. 3).
Univariate analysis of laboratory and clinical parameters
from the follow-up period showed that admission creatinine
[1.4 mg/dl (RR: 1.58 [1.15–2.04]; p = 0.03), admission
eGFR \45 ml/min1.73 m2 (RR 1.69 [1.23–2.10];
p = 0.01) and BNP levels at discharge [500 pg/ml (RR:
2.06 [1.65–2.57]; p = 0.01) are all predictors of a poor
outcome. On the other hand, neither BNP level at admis-
sion (RR: 0.94 [0.72–1.87]; p = 0.18) nor creatinine level
at discharge (RR: 1.12 [0.77–1.53]; p = 0.25) and eGFR at
discharge (RR: 0.81 [0.35–1.24]; p = 0.14) demonstrate
any significant impact (Table 4).
Discussion
The use of loop diuretics is essential in the management of
HF, particularly during episodes of acute recurrent failure
[3]. Although its use is approved by International Guide-
lines, currently there are no specific recommendations that
show a clear benefit in HF outcome regarding both the
administration modalities and the dosing [11]. Many
authors believe that a dosage administration is merely a
marker of disease severity, pointing to a higher degree of
hemodynamic and kidney impairment [12, 13].
Our results demonstrate that despite a significant
increase in the volume of the diuresis and a significant
reduction of BNP levels in cIV group, there is a trend
towards a higher rate of AKI during the hospitalization
period in the same group when compared to the iIV arm.
Moreover, the exact role of impaired renal function during
hospitalization is currently under debate: some authors
consider it as an important target and prognostic indicator,
while others believe it is merely the final equivalent of
systemic hemodynamic and neuroendocrine unbalance
[14–16]. In our sample, worsening renal function during
the hospitalization period seemed to have less clinical
impact compared to the post discharge period.
Patients with cIV need more additional support therapy
(saline solution and dobutamine) and a longer hospital stay.
Although no differences in terms of adverse events were
found between both groups during the hospitalization
period, the post discharge period revealed a trend towards a
worse prognosis in cIV (RR 1.46 [1.13–2.08], p \ 0.05).
These findings appear linked much more to basal renal
dysfunction (RR 1.58 [1.15–2.04], p \ 0.03) instead of
impaired renal function at discharge as revealed by uni-
variate analysis (Table 4). Nevertheless, we observed an
apparent paradox consisting in BNP decrease associated
with an impaired renal function in patients who were
Fig. 3 a Difference in dopamine infusion between IiV (blue
columns) and CiV (red columns) groups; b difference regarding
hospitalization up than 10 gg between IiV (blue columns) and CiV
(red columns); c difference in dopamine infusion between IiV (blue
columns) and CiV (red columns) groups; and d difference in BNP
values at discharge between IiV (blue columns) and CiV (red
columns)
Table 4 Univariate analysis of clinical predictors for adverse out-
come including mortality and readmission for heart failure and other
cardiac events or acute renal insufficiency
Parameters Risk
ratio
95 % CI of risk
ratio
p value
Hospital stay ([10 days) 1.43 1.25–1.77 0.01
Creatinine ([1.4 mg/dl)
at baseline
1.58 1.15–2.04 0.03
Creatinine ([1.5 mg/dl)
at discharge
1.12 0.77– 1.53 0.25
eGFR (\45 ml/min1.73/m2)
at baseline
1.69 1.23–2.10 0.01
eGFR (\45 ml/min1.73/m2)
at discharge
0.81 0.35–1.24 0.14
BNP ([500 pg/ml)
at discharge
2.06 1.65–2.57 0.01
BNP ([500 pg/ml)
at admission
0.94 0.72–1.87 0.18
Hypersaline solution 1.13 0.84–1.46 0.08
Dobutamine infusion 1.49 1.06– 1.98 0.04
Continuous vs intermittent
therapy
1.46 1.13–2.08 0.05
eGFR estimated glomerular filtration rate, BNP brain natriuretic
peptide, IC confidence interval
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submitted to a continuous treatment: some potential
confounding contributors could be due to the worse
hemodynamic and metabolic status linked to the modality
of administration. Even if clinical and laboratory param-
eters are similar in the two groups, patients submitted to
cIV may be exposed to more persistent kidney damage,
which promotes neuroendocrine overdrive, leading to
increased tubulo-glomerular feedback [2, 11]. In clinical
practice, the use of loop diuretic is often empirical and
established by physicians’ experience instead of specific
protocols and evidence. Besides, the impaired renal
function during Acute HF hospitalization is a common
phenomenon to which different authors assign different
weight and importance: several studies indicate that
worsening renal function is related to increased mortality
and readmission, however, recent trials have questioned
these findings. Nevertheless, it remains unclear whether
WRF itself contributes to the poor outcome, or whether it
is merely a marker of a more decompensated HF [14, 15,
18–20]. In patients with the Cardio-Renal syndrome
treated with elevated doses of diuretics, compensatory
pathophysiological mechanisms to maintain vascular
resistance, such as non-osmotic stimulation of vasopressin
secretion and activation of the renin angiotensin system
(RAAS), have been observed [21]. Diuretic resistance is
another factor often associated with WRF, and it may
play a potential role in the occurrence of adverse effects.
Therefore, hyponatremia is an associated clinical condi-
tion that could have a causal relationship that by itself
leads to a diuretic resistance [22]. Although hyponatremia
was not one of our primary endpoints, our findings evi-
denced that cIV infusion could impoverish Na? supplying
with respect to iIV administration: the intermittent
modality could avoid this event by salvaging Na? during
a stop period.
The role of loop diuretics, their dosage, and the modality
of administration, remain to be elucidated: recent analyses
suggest that higher doses of diuretics are necessary in
severe cases with more impaired renal function, thus
adverse effects may result from disease severity [23]. In
this context, Felker et al. [8] have recently published a
multi-centre trial comparing loop diuretic dosages and
administration modalities. Our findings provide evidence
that both treatments are comparable on hard end-points
during the early follow-up period, and they could not
reveal a benefit of any one of the modality of treatments.
Respect to the cited Trial, our study evaluated a longer
follow-up period in patients with higher mean loop diuretic
dosage. However, our results are in accordance with the
DOSE trial: the Felker study does not reveal a different
outcome despite worsening renal function in the cIV arm.
These apparently contradictory data could be explained by
several observations: the pathophysiological mechanism of
the renal injury could be different in distinct reports and
patients, moreover, blood pressure values and blood renal
perfusion need to be included in the analysis. Therefore,
additional therapy including exact fluid administration
modality, and different diuretic protocol administration, are
all confounding factors and potential biases [14, 20, 23].
Other studies in this field demonstrate conflicting results.
Allen et al. [24] do not show any difference in hospital
stay, urine output and creatinine levels between bolus and
continuous infusion. On the other hand, Thomson et al.
[25] show more favorable effects in the continuous arm,
although a different diuretic dose administration was uti-
lized in the different groups. These controversial findings
could be due to the different etiology of renal dysfunction
or different treatment protocols of administration. In this
sense in our protocol we used a significant higher dosage
respect to the previous published studies in which the mean
dosage was 120 mg/die. All these concerns could partially
explain some differences with respect to the literature.
Perhaps our patients were sicker with more advanced
congestion compared to previous studies.
Although our univariate analysis was executed in a
small sample size, it demonstrated that BNP at discharge,
baseline renal dysfunction and dobutamine infusion are the
factors capable of predicting hospitalization and mortality
rates during the follow-up period. From this point of view,
our sample appears to have similar characteristics in
comparison to the larger studies on ADHF [26, 27].
The BNP values trend deserves a more specific con-
sideration: most trials demonstrate that a reduction of BNP
is related to improved outcomes [28, 29]. Although we did
not observe a more favorable outcome in group with cIV,
analysis of all patients at discharge confirmed that a BNP
cut off[500 pg/ml remains a potential predictor of higher
adverse events rate. The current discrepancy could be due
to the small number of patients studied, or to the difference
in additional therapy between groups. Alternatively, we
could hypothesize the prognostic impact of WRF should be
more important with respect to BNP reduction. Taken
altogether, these data suggest that loop diuretic efficacy is
far from being universal. Further studies are required to
determine whether high-dose diuretics are responsible for
worsening renal function, and whether a higher rate of
coexisting renal disease could be a marker of more severe
heart failure.
Limitations
Although patients were randomly assigned to the treatment
groups, this was not a blinded study. However, the mean
dose administration and the clinical characteristics in both
groups at randomization were similar. There are some
Intern Emerg Med (2015) 10:41–49 47
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biases in the study protocol due to titration of furosemide
dose according to the response, and non-uniform standard
therapy (i.e., nitrate, ACE inhibitors, beta blockers) how-
ever, the mean dose of diuretic was similar in the two
groups. Results could be partially influenced by the diuretic
dose regime during the first 12 h before randomization.
After the first 24 h of randomization, the titration of the
furosemide dosage was guided based on the patient’s
response to the treatment. Most of the patients received
open-label diuretic therapy during the period before ran-
domization and admission to the hospital. For these reasons
our findings cannot be extended to patients with newly
diagnosed HF or to those with lower diuretic requirements.
Our study did not explain the reasons for the decreased
renal function during treatment, which could indicate a
different pathophysiological disorder linked alternatively
to a primitive renal disease, or secondary to infusion
treatment or congestion. Concurrent evaluation of blood
urea nitrogen could further clarify the primary defect. This
is the next topic we would like to study in a larger sample.
Infusion intake was not controlled since urine output and
renal function could have been influenced. This was a
single centre small non blinded study, it is prone to several
forms of bias due to the nature of the protocol and inter-
vention as well as to a lack of statistical power across any
outcome. The multivariate analysis could be inadequate
because of small sample size, and follow-up data should be
taken with caution, for these reasons we intend to continue
enrollment. Our study-sample was small, and was unsuc-
cessful at detecting small but potentially significant dif-
ferences in laboratory parameters, neither did it point to
large differences in clinical outcomes. Therefore, our
results may not be suitable for extension to other settings or
populations.
Conclusions
In this preliminary, pilot study, cIV appears to provide a
better BNP reduction and a more efficient diuresis in
comparison to iIV, in patients with acute HF and renal
dysfunction. However, continuous administration is asso-
ciated with an increased rate of AKI after infusion treat-
ment, longer hospital stay and the need for additional
therapy. Moreover, cIV is related to impaired long-term
outcome. For all of these reasons larger multi-centre
studies appear mandatory to define the best approach and
modality of administration.
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